| Course | NR 567 Advanced Pharmacology for the Adult Gerontology Acute Care Nurse Practitioner |
|---|---|
| Week | 6 |
| Paper type | Empiric antimicrobial rationale |
| Length | About 1,110 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Adult-Gerontology Acute Care NP (AGACNP) |
| Updated | October 2026 |
Free sample paper for NR 567 Week 6
Empiric Antimicrobial Rationale: Severe Community-Acquired Pneumonia With Septic Shock After a Recent Hospital Stay, Coverage Widened One Agent at a Time and a 48-Hour Review Written In
Student Name
College of Nursing, Chamberlain University
NR 567: Advanced Pharmacology for the Adult Gerontology Acute Care Nurse Practitioner
Instructor Name
Month Day, Year
Empiric Antimicrobial Rationale: Severe Community-Acquired Pneumonia With Septic Shock After a Recent Hospital Stay, Coverage Widened One Agent at a Time and a 48-Hour Review Written In
The Source, Argued
On day 1, the composite patient followed through this course arrived with five days of cough, fever and increasing breathlessness, then confusion on the morning of admission. Oxygen saturation was 84% on room air. The chest radiograph showed dense right lower lobe consolidation with air bronchograms and a small effusion, and bedside ultrasound showed lung consolidation with dynamic air bronchograms and a thin, free-flowing effusion without loculations. The urine was clear, the abdomen soft and nontender, the skin intact apart from a healed leg wound, and the central and peripheral lines had been placed in the emergency department that day. The source is pneumonia, supported by examination and imaging rather than assumed. Septic shock was present: mean arterial pressure 58 mm Hg after fluids and a lactate of 4.1 mmol/L.
The Host That Widens It
For severe community-acquired pneumonia in a patient without risk factors, guidance recommends a beta-lactam such as ceftriaxone plus a macrolide (Metlay et al., 2019). Each agent beyond that baseline must have a reason attached.
Methicillin-resistant Staphylococcus aureus coverage is added because the patient was hospitalized five weeks ago for leg cellulitis and received intravenous antibiotics, and guidance supports empiric coverage for this organism in severe pneumonia when recent hospitalization and parenteral antibiotics are present and local data support the risk (Metlay et al., 2019). Vancomycin is chosen.
Pseudomonas coverage is added for the same reason: recent hospitalization with intravenous antibiotics raises the risk of resistant gram-negative organisms. The beta-lactam therefore moves from ceftriaxone to cefepime.
Macrolide coverage is kept, with azithromycin, for atypical organisms and because combination therapy with a macrolide is preferred in severe pneumonia (Metlay et al., 2019).
No antifungal or antiviral is added. A rapid respiratory panel was negative for influenza and SARS-CoV-2.
What Was Deliberately Not Covered
A rationale is also defined by what it leaves out. Anaerobic coverage was not added: there was no aspiration event, no lung abscess on imaging and no poor dentition, so adding metronidazole or switching to a broader agent would add toxicity without benefit. Antifungal therapy was not added, because the patient had no neutropenia, no recent broad-spectrum exposure beyond one cefazolin course and no other risk for invasive candidiasis. Coverage for resistant gram-negative organisms beyond cefepime, such as a carbapenem, was not added, because the patient had no history of an extended-spectrum beta-lactamase organism and no recent carbapenem exposure. Each omission is written down so that the reviewing team can see that it was a decision rather than an oversight, and so that a change in the patient's course can be checked against the reasons.
Why Speed Mattered
In septic shock, antibiotics should be given as soon as possible, ideally within an hour of recognition (Evans et al., 2021). That is why the first doses were drawn up in the emergency department while the central line was being placed, and why the loading dose of vancomycin was started through a peripheral cannula rather than waiting for central access.
The time of each first dose was charted against the time shock was recognized, so that the hospital's sepsis review can check whether the one-hour goal was met and where any delay occurred.
The First Dose, in Full
All first doses are given at full strength, whatever the kidney function. The patient's creatinine was 2.1 mg/dL on arrival and rising, but the first dose of an antibiotic fills the volume of distribution and does not depend on clearance. Reducing it because of the kidneys undertreats at the most dangerous hour.
Cefepime 2 g intravenously, first dose given within the first hour.
Vancomycin loading dose 25 mg/kg of actual body weight, 2,250 mg, infused over two hours (Rybak et al., 2020).
Azithromycin 500 mg intravenously.
Maintenance doses are then set by the pharmacist according to kidney function and, from day 2, the clearance provided by continuous hemodiafiltration. For cefepime, that is 2 g every 12 hours at the planned effluent rate, with attention to neurotoxicity, which is more common when the drug accumulates.
Specimens and Source Control
Before the first antibiotic dose, two sets of blood cultures were drawn from separate sites, and an endotracheal aspirate was sent for Gram stain and culture immediately after intubation. A methicillin-resistant Staphylococcus aureus nasal PCR, urine pneumococcal antigen and urine Legionella antigen were sent at the same time. Antibiotics were not delayed for these specimens, but none was skipped.
Source control in pneumonia usually means draining an infected pleural space. The effusion is small and free-flowing, so it is not tapped now; it will be reassessed by ultrasound in 48 hours, and a diagnostic tap will be done if it enlarges or becomes loculated, since an empyema would need drainage.
The Review Point
At 48 hours, the team reviews the regimen against the results, and the plan is written now so that it happens.
If the nasal PCR is negative and no Staphylococcus aureus grows from blood or sputum: stop vancomycin. A negative nasal PCR has a high negative predictive value for MRSA pneumonia, which supports stopping empiric coverage (Parente et al., 2018).
If an organism is identified: narrow to the most targeted agent. For a penicillin-susceptible Streptococcus pneumoniae, that means ceftriaxone 2 g daily, which needs no dose adjustment on dialysis.
If no Pseudomonas grows: stop cefepime in favor of the narrower agent.
Azithromycin: continue for a total of three to five days.
Duration: at least five days in total, with clinical stability before stopping, longer if bacteremia or complications occur (Metlay et al., 2019).
Day 2 Results
On day 2, as this rationale was being completed, the sputum Gram stain showed gram-positive diplococci, both blood culture sets grew Streptococcus pneumoniae, the urine pneumococcal antigen was positive, and the nasal PCR was negative. The 48-hour review will confirm susceptibilities and is expected to narrow therapy to ceftriaxone, with vancomycin stopped. Because the patient is bacteremic with pneumococcus, the total duration will likely be about seven days if recovery is steady.
The narrowing decision and its date are entered with a planned stop date at the same time, so that the course cannot run on by default after the switch.
References
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., Schorr, C., Simpson, S., Wiersinga, W. J., Alshamsi, F., Angus, D. C., Arabi, Y., Azevedo, L., Beale, R., Beilman, G., . . . Levy, M. (2021). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Critical Care Medicine, 49(11), e1063-e1143. https://doi.org/10.1097/CCM.0000000000005337
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 200(7), e45-e67. https://doi.org/10.1164/rccm.201908-1581ST
Parente, D. M., Cunha, C. B., Mylonakis, E., & Timbrook, T. T. (2018). The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: A diagnostic meta-analysis with antimicrobial stewardship implications. Clinical Infectious Diseases, 67(1), 1-7. https://doi.org/10.1093/cid/ciy024
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., Rodvold, K. A., Maples, H. D., & Lomaestro, B. M. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 77(11), 835-864. https://doi.org/10.1093/ajhp/zxaa036
Reading the NR 567 Week 6 instructions
The empiric antimicrobial rationale usually asks you to choose antibiotics before cultures return and to explain when and how you will narrow them. Expect the prompt to ask for the suspected source, risk factors, the regimen, doses, cultures and a de-escalation plan. Argue the source from examination and imaging rather than assuming it. Start from the guideline baseline and add each extra agent only with the host factor that justifies it. State what you are not covering and why. Give the first dose of each drug in full, regardless of kidney function. List the specimens taken before antibiotics, consider source control and fix a review point with the results that would narrow or stop each drug.
Inside the NR 567 Week 6 example
The sample sets out the history, oxygen saturation, radiograph and bedside ultrasound, and confirms septic shock. It begins from the guideline baseline of ceftriaxone with a macrolide, then adds vancomycin and moves to cefepime because of a recent hospital stay with intravenous antibiotics, keeping azithromycin. A section explains why anaerobic, antifungal and carbapenem coverage were left out. First doses are written in full, with a note on cefepime neurotoxicity. Specimens include blood cultures, an endotracheal aspirate, a nasal PCR and urine antigens, and the effusion is assessed for drainage. The 48-hour review states rules for stopping vancomycin, narrowing to ceftriaxone and duration, and day 2 results show pneumococcal bacteremia with a negative PCR.
Reading the NR 567 Week 6 grading rubric
Empiric rationales here are typically judged on an argued source, coverage that widens for stated reasons, full first doses, specimens collected before therapy, attention to source control and a fixed review point. Broad coverage with no source loses the most, so this sample supports pneumonia with examination and imaging. Each agent beyond the baseline arrives with its host factor, which shows the regimen is reasoned. Recording what was deliberately left out demonstrates judgment. Giving first doses in full despite kidney injury avoids a well-intentioned but harmful error. Specimens and ultrasound for the effusion keep narrowing and source control possible. A review point with rules for each drug, followed by day 2 results, shows the timetable working. Citations support the regimen and the PCR rule.
NR 567 Week 6 help: mistakes that cost points
The most expensive error in this week is broad coverage with no source, which turns a rationale into a list. Another is reducing the first dose for a poor kidney, which undertreats when it matters most. Many papers forget to take cultures before antibiotics, or never mention source control. Some add agents without saying which risk factor justifies them. Others give no review point, so the empiric regimen continues by default for days. Argue the source, widen one agent at a time with reasons, give full first doses, take specimens, consider drainage and set a 48-hour review. A rationale for a different source, such as an abdominal or urinary infection, can be written from your case details.
Get a NR 567 Week 6 example written to your instructions
Send us the Week 6 prompt as issued, plus the source and the host you want the rationale built on, and a custom example is written to it and returned within 24-48h. The first one is free. If a local antibiogram or a particular guideline has to be cited, name it and it is used.
More NR 567 papers and AGACNP samples
- NR 567 Week 1: Status Epilepticus Route Discussion
- NR 567 Week 2: CRRT Vancomycin Dosing Brief
- NR 567 Week 3: Nicardipine Titration Plan
- NR 567 Week 4: Septic Shock Vasopressor Write-Up
- NR 567 Week 5: ICU Sedation and Analgesia Plan
- NR 567 Week 7: Anticoagulation Case Analysis
- NR 567 Week 8: De-escalation Plan
NR 567 Week 6 questions, answered
How wide should the initial coverage be?
Wide enough for the likely organisms at the named source in this particular host, and no wider. Every extra agent is defended by a host factor or it is anxiety on the page. What separates a strong rationale is not breadth anyway, it is that the writer has already said which finding would let the coverage come off.
Does a failing kidney change the first dose?
Not the first one, and this gets examined. The loading dose is driven by the space the drug distributes into, which resuscitation has usually made larger, so somebody with a failing kidney still receives a full first dose. Adjustment belongs to the doses that follow it. Shrinking the front of the course is the error that turns up most often.
Where does source control fit?
Inside the prescription, not beside it. A collection that has not been drained, a line still sitting in a vein and a dead segment of bowel are all reasons the antimicrobial will fail whatever gets chosen. Rationales treating the drug as the entire answer read as pharmacology written at a distance from the patient it belongs to.
Where can I find a free NR 567 Week 6 sample paper?
The pneumonia rationale above, with coverage widened one agent at a time and a 48-hour review written in advance, is the complete NR 567 Week 6 sample. Another infection source can be argued the same way on request.
When is vancomycin stopped in the NR 567 Week 6 rationale?
At the 48-hour review, if the MRSA nasal PCR is negative and no Staphylococcus aureus grows from blood or sputum, because a negative PCR makes MRSA pneumonia unlikely.